Benson C A, Kessler H A
Section of Infectious Disease, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
Compr Ther. 1988 Mar;14(3):58-64.
The widespread application of molecular virologic technology has resulted in a rapid expansion in our knowledge of the physical, biologic, and clinical properties of EBV. As data continue to accumulate, we may better understand the pathogenesis of, and more clearly define diseases associated with, primary and reactivated infection due to this virus. The development of new antiviral agents and recombinant or subunit vaccines will permit more effective treatment, and possibly prevention, of disease and long-term sequelae associated with EBV infection.
分子病毒学技术的广泛应用使我们对EB病毒的物理、生物学和临床特性的了解迅速扩展。随着数据不断积累，我们可能会更好地理解这种病毒引起的原发性和再激活感染的发病机制，并更清楚地界定与之相关的疾病。新型抗病毒药物以及重组或亚单位疫苗的研发将使与EB病毒感染相关的疾病及其长期后遗症得到更有效的治疗，甚至可能实现预防。
